PHARMACOLOGICAL PROFILE OF LOOP DIURETIC IN EXPERIMENTAL MODEL OF HEART FAILURE

• DOI: 10.22533/at.ed.1592192208047

• Palavras-chave: Loop diuretics, Heart failure, Health.

• Keywords: Loop diuretics, Heart failure, Health.

• Abstract:

  Loop diuretics such as furosemide are first-line drugs for patients with decompensated heart failure (HF). The study aims to describe the implementation and standardization of an experimental model in diuresis at the Laboratory of Research and Graduate Studies in Pharmacology at the Federal University of Maranhão. Rats were randomly divided: furosemide (furosemide) group received 10 mg/kg furosemide, without CI; The Heart Failure Group (Vehicle-HF) received 10ml/kg of water and the Heart Failure-Furosemide Group (Furosemide-HF) received 10mg/kg of furosemide. IC was induced by isoproterenol for seven days. The oral treatment took place for 7 days to assess food and water intake, weight gain, urinary volume, excretion, and diuretic activity. The rodents with HF showed cardiac hypertrophy and body weight loss in the induction process. Regarding the impacts of HF on water consumption, the animals with heart disease showed intense water intake compared to the Furosemide Group. During treatment, there was a significant drop in water consumption in these groups, a change that is not evident on the last day of treatment among the groups evaluated. There was no change in feed consumption. The HF-vehicle and HF-furosemide groups showed a reduction in 24-hour urinary volume, urinary excretion, and diuresis, on the 7th day of treatment, when compared to the healthy group, treated with the diuretic. The results allow identifying the deleterious impacts of the induction of CI on the renal capacity of the animals, reducing the urinary volume and urinary excretion, where the diuretic activity of furosemide was compromised without it being able to induce with the expected effectiveness, its activity on the animal renal system. The data studied identified patterns in the diuresis protocol in animals with heart failure, with possibilities for future pharmacological investigations.

• Número de páginas: 18